secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2022-07-20T23:59:59+00:00
Accession:  0001213900-22-040385
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed appoints Michael Woudenberg as COO effective July 15, 2022
----------------------------------------------------------------

- Michael Woudenberg appointed Chief Operating Officer, effective July 15, 2022.
- Previously served as SVP of Chemistry, Manufacturing and Controls.
- Employment agreement provides C$300,000 annual base salary.
- Eligible for annual discretionary bonus targeted at 40% of base salary.
- Woudenberg has over 20 years of drug development and GMP manufacturing experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022040385/0001213900-22-040385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022040385/ea163069-8k_inmedpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-040385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer